Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications.
about
Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationMetal pollutants and cardiovascular disease: mechanisms and consequences of exposurePhysiology and pathophysiology of carnosine.Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivityIncreased Dicarbonyl Stress as a Novel Mechanism of Multi-Organ Failure in Critical IllnessTendinopathy in diabetes mellitus patients-Epidemiology, pathogenesis, and management.Dietary Metabolites and Chronic Kidney Disease.Research on the traditional Chinese medicine treating gastrointestinal motility in diabetic rats by improving biomechanical remodeling and neuroendocrine regulation.EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT)Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.The role of microglia in diabetic retinopathyInhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal WomenPentosidine levels in nonproteinuric diabetes associated with both low estimated glomerular filtration rate and cataractCarbonylation induces heterogeneity in cardiac ryanodine receptor function in diabetes mellitus.Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.Mitigation of diabetes-related complications in implanted collagen and elastin scaffolds using matrix-binding polyphenol.Diabetes in early pregnancy: getting to the heart of the matter.Uremic Toxicity of Advanced Glycation End Products in CKD.Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairmentCrystal structure of bis-{4-bromo-2-[(carb-amim-id-amido-imino)-meth-yl]phenolato-κ(3) N,N',O}cobalt(III) nitrate di-methyl-formamide monosolvate.Methanolic Extract of Dill Leaves Inhibits AGEs Formation and Shows Potential Hepatoprotective Effects in CCl4 Induced Liver Toxicity in Rat.Molecular biomarkers of lung carcinoma.Glycated proteome: from reaction to intervention.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation.Baking, ageing, diabetes: a short history of the Maillard reaction.The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.Prevention of protein glycation by natural compounds.EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients.Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease.N-Phenacylthiazolium bromide inhibits the advanced glycation end product (AGE)-AGE receptor axis to modulate experimental periodontitis in rats.Chronic Toxic Metal Exposure and Cardiovascular Disease: Mechanisms of Risk and Emerging Role of Chelation Therapy.Vascular endothelium in diabetes.Dissecting copper homeostasis in diabetes mellitus.On the Anticataractogenic Effects of L-Carnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor?Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.
P2860
Q26751110-B6D84289-A25B-4C7A-8C2F-3A58938700C3Q27023569-227803E7-A4C4-4C8A-8A5A-BFA3E600BD02Q27692648-DB4CE4E4-640A-4544-8DC2-CB5EC6F455B0Q28542711-5B2C5AA7-1204-47D7-AFA8-1213149C82D8Q30236047-C5BCA551-A3C7-4F48-8B69-741B08A50501Q30238916-5DA440CA-5D5F-41DE-99FB-9253BDB5DAEEQ33616732-B71FC787-EBFA-4717-8976-33729A7F64B9Q33733145-F9E09D29-A3C5-4B1F-A4D3-05D47791F5E5Q33801879-8DF3339C-93F9-46E1-A952-75E73E896FD0Q33952145-3E0CE2D9-894F-4CB9-8118-31CE3CE7304FQ34124558-255EFD75-6101-4942-A8AC-B32AE22A90D2Q34199146-4088E53B-8D66-46CB-BB88-AE8388DF87C3Q34983879-E8CE03F1-4459-4373-9BD1-36BE55D176CBQ36047141-B082A7CC-734B-45A9-A680-EEC43A841409Q36092468-E0432546-9EB8-41C3-B37A-9E302114F273Q36174773-E799BB2E-37C0-43BD-B4E2-20206DA19648Q36372679-D1C0FCFE-4D41-497D-ABBF-99CBD57A0B7DQ36392793-EFFE6860-09D9-4005-8264-AE1B9D852637Q36477243-AB2BE021-6AD2-4C37-A0E3-1E8BDE30B16BQ36514906-5F39241B-68DC-4305-9FA6-9ABA509019E4Q36698294-AF59756E-CF2B-437E-8191-DFCCB4098618Q37193283-8C6DD010-F274-484F-81C1-07244487AAE4Q37611305-3EEF098B-3FFF-49FB-81B7-1824ECA3067CQ37971659-A4E99D27-6EFA-4070-A357-B9312B2CCA73Q38062900-A1E86AC4-5C65-4155-B0FA-D1DCD7853765Q38070906-02001FF4-DF70-48D7-86C3-E236A35C8C4AQ38096444-A1615C2D-02EC-43DC-8CFC-6F3013A6CD91Q38221639-937391E7-93E8-4B56-B7BF-0681E98D4D9FQ38232036-F4A1F017-8A11-4660-A286-AD474A90ABE4Q38241689-3DD508E3-E9A6-435E-9D73-DCCF4FC79A02Q38358965-500143B8-15E4-42ED-929B-BEFB43FB69DCQ38585738-76D41B52-26BA-42B7-8248-471369170059Q38707380-4B027F18-CB65-416C-959D-59AD426039DBQ38777574-8041DEBC-FC19-41CA-9B49-CFEC78860218Q38978758-50B157F6-07F7-453D-A3F7-A47C380E5FCDQ39002320-4AD9ACC8-1D8A-49D0-9954-FA42A1BD1947Q39010377-97AB8BAF-B550-4D9C-B943-3D25582E917DQ39169920-3D637D49-D7FD-4C96-BE50-34A0B0539463Q39206601-1C492341-F0A2-449D-99B2-8B3D55604AF4Q39285661-887B10EC-C331-4405-A468-2AE780130497
P2860
Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Chelation: a fundamental mecha ...... ors of diabetes complications.
@ast
Chelation: a fundamental mecha ...... ors of diabetes complications.
@en
type
label
Chelation: a fundamental mecha ...... ors of diabetes complications.
@ast
Chelation: a fundamental mecha ...... ors of diabetes complications.
@en
prefLabel
Chelation: a fundamental mecha ...... ors of diabetes complications.
@ast
Chelation: a fundamental mecha ...... ors of diabetes complications.
@en
P2093
P2860
P921
P356
P1433
P1476
Chelation: a fundamental mecha ...... ors of diabetes complications.
@en
P2093
David B Murray
John W Baynes
Ryoji Nagai
P2860
P304
P356
10.2337/DB11-1120
P407
P50
P5008
P577
2012-03-01T00:00:00Z